For the nine months ended December 2025 (Q3 YTD) of FY ending March 2026, consolidated results were Revenue ¥144.3B (YoY +¥3.3B +2.4%), Operating Income ¥7.2B (YoY +¥0.5B +7.3%), Ordinary Income ¥7.5B (YoY +¥0.8B +11.5%), and Net Income attributable to owners of parent ¥4.7B (YoY +¥0.2B +4.4%), achieving topline growth with higher profits across all profit lines versus the prior-year period. The Operating Margin was 5.0%, improving by 0.2pt from 4.8% last year, and the Ordinary Income Margin was 5.2%, up 0.4pt from 4.8% last year. Ordinary Income exceeded Operating Income, indicating contributions from non-operating income. Net Income attributable to owners of parent was compressed relative to Ordinary Income due to a high effective tax rate of 44.4%. Total assets were ¥285.6B (vs. prior FY-end +¥42.3B), net assets were ¥159.7B (vs. prior FY-end +¥11.1B), and the Equity Ratio remained at 55.9%.
Revenue: The YoY +2.4% increase was driven by the product segment “Chemical Products Business” with revenue of ¥131.3B and the “Environmental Business” with revenue of ¥13.2B, continuing a moderate growth trend. The PDF suggests a recovery backdrop led by rising inbound demand and improvements in employment and income conditions. Gross profit was ¥17.1B (gross margin 11.9%), maintaining a certain margin under cost control.
P/L: Operating Income was ¥7.2B (+7.3% YoY), outpacing the sales growth. The 5.0% Operating Margin improved by 0.2pt from 4.8% last year, suggesting effective control of SG&A. Ordinary Income was ¥7.5B (+11.5%), with non-operating income lifting Operating Income by roughly ¥0.3B, likely from dividend income and foreign exchange gains. Profit before tax rose to ¥8.4B, but Net Income attributable to owners of parent was limited to ¥4.7B (+4.4%) due to a high effective tax rate of 44.4%. While details of extraordinary gains/losses were not disclosed, the difference between Profit before tax and Ordinary Income (approximately ¥0.9B) suggests recognition of extraordinary gains. Comprehensive income significantly improved to ¥12.3B, mainly due to ¥7.7B in net unrealized gains on available-for-sale securities, reflecting unrealized gains on investment securities. However, this is a temporary and non-cash item, and consistency with Operating Cash Flow (OCF) needs to be confirmed.
Conclusion: The company achieved Revenue +2.4% and Operating Income +7.3%, with Ordinary Income also delivering double-digit growth at +11.5%. However, due to a high tax burden, Net Income growth was limited to +4.4%, dampening the profitability improvement at the bottom line.
Chemical Products Business: Revenue ¥131.3B, Operating Income ¥5.2B (Operating Margin 4.0%). This is the core business, accounting for 91.0% of consolidated revenue, with a broad product lineup including pharmaceutical intermediates, semiconductor materials, electronic materials, film materials, photographic materials, printing materials, and display materials. Operating Income of ¥5.2B accounts for 72.2% of consolidated Operating Income of ¥7.2B, underpinning group profitability. Although YoY comparisons were not disclosed, the full-year outlook indicates flat Operating Income, suggesting limited margin improvement in the Chemical Products Business.
Environmental Business: Revenue ¥13.2B, Operating Income ¥1.9B (Operating Margin 14.4%). While this is a secondary business accounting for 9.1% of consolidated revenue, it is a highly profitable segment with an Operating Margin significantly higher than the 4.0% in Chemical Products. Operating Income of ¥1.9B represents 26.4% of consolidated Operating Income, indicating a high contribution relative to its scale. A key feature is the established environmental management system (ISO 14001 certified) and the promotion of an environmental policy.
While the core Chemical Products Business drives roughly 90% of sales, its Operating Margin is limited to 4.0%. By contrast, the Environmental Business, though smaller, is highly profitable with a 14.4% Operating Margin, and is notable for its future growth potential. Although the detailed segment breakdown behind profit growth was not disclosed, given the scale, the Chemical Products Business likely drove the overall increase in profits.
Profitability: ROE 2.9% (no comparison due to prior FY-end data not disclosed), Operating Margin 5.0% (+0.2pt from 4.8% in the prior-year period), Net Margin 3.2%, Ordinary Income Margin 5.2%. Under the DuPont three-factor breakdown, the 2.9% ROE is composed of Net Margin 3.2%, Total Asset Turnover 0.505x, and Financial Leverage 1.79x. ROIC at 2.2% indicates low capital efficiency.
Cash quality: OCF and the OCF/Net Income ratio are undisclosed; therefore, assessment is not possible. Free Cash Flow is also undisclosed.
Investment efficiency: With no disclosure of CapEx and depreciation, the CapEx/depreciation multiple cannot be calculated.
Financial soundness: Equity Ratio 55.9% (down -5.2pt from 61.1% at the prior FY-end), Current Ratio 201.7%, Quick Ratio 183.9%. Cash and deposits are ¥31.9B against short-term borrowings of ¥15.0B, implying a Cash/Short-term Debt ratio of 2.13x, a solid level. Interest-bearing debt is ¥53.2B, Debt-to-Equity ratio 0.79x, and Debt/Capital ratio 25.0%, maintaining a conservative capital structure. However, long-term borrowings increased significantly by +79.9%, from ¥21.3B at the prior FY-end to ¥38.3B.
OCF, investing CF, financing CF, and CapEx were not disclosed in either the earnings release (XBRL) or the PDF materials; therefore, a cash flow analysis cannot be conducted. At present, comparisons between OCF and Net Income, Free Cash Flow calculation, and juxtaposition with dividends and share buybacks cannot be evaluated. Cash and deposits increased by ¥3.9B from the prior FY-end to ¥31.9B, suggesting comfortable liquidity; however, the increase in borrowings (long-term borrowings +¥16.97B, short-term borrowings +¥1.00B) may have contributed to the cash increase. Of the ¥12.3B in comprehensive income, Net Income for the period was ¥4.7B, with most of the difference attributable to ¥7.7B in net unrealized gains on available-for-sale securities, indicating that the uplift in comprehensive income was driven by non-cash items—this warrants attention. After OCF disclosure, if the OCF/Net Income ratio falls below 1.0x, it would be a warning sign regarding earnings quality.
Cash generation assessment: Deferred due to insufficient data (monitoring required).
Ordinary Income ¥7.5B vs. Net Income ¥4.7B: The decrease from Ordinary Income to Net Income was ¥2.8B (-37.3%), mainly due to the high effective tax rate of 44.4%. The ¥0.9B gap between Profit before tax of ¥8.4B and Ordinary Income of ¥7.5B suggests recognition of extraordinary gains, potentially from gains on sale of fixed assets or investment securities. However, the breakdown of extraordinary gains/losses is undisclosed, and details are unknown.
Non-operating income: Ordinary Income exceeded Operating Income by about ¥0.3B, indicating contributions from non-operating income. Against Revenue of ¥144.3B, non-operating income of ¥0.3B is 0.2% of Revenue, and its impact on the earnings structure is limited.
Accruals: With OCF undisclosed, the gap (accruals) between OCF and Net Income cannot be assessed. Comprehensive income of ¥12.3B significantly exceeded Net Income of ¥4.7B due to ¥7.7B (non-cash) in net unrealized gains on available-for-sale securities, which lacks OCF backing; hence, attention to earnings quality is warranted.
Full-year forecast (FY ending March 2026): Revenue ¥195.0B (YoY +4.6%), Operating Income ¥8.3B (YoY -2.1%), Ordinary Income ¥8.7B (YoY +6.2%), Net Income attributable to owners of parent ¥7.7B.
Progress rate versus full-year guidance at Q3 YTD: Revenue 74.0% (¥144.3B/¥195.0B), Operating Income 86.7% (¥7.2B/¥8.3B), Ordinary Income 85.9% (¥7.5B/¥8.7B), Net Income 60.6% (¥4.7B/¥7.7B). Relative to the standard Q3 progress rate (75%), Revenue is roughly on track (-1.0pt), Operating Income is meaningfully ahead (+11.7pt), and Ordinary Income is also ahead (+10.9pt). Conversely, the Net Income progress rate of 60.6% is well below standard (-14.4pt).
The outperformance in Operating Income and Ordinary Income suggests an assumption of profit decline in Q4. The full-year Operating Income forecast of ¥8.3B implies a YoY decrease of -2.1%, with Q4 standalone Operating Income expected to slow sharply to ¥1.1B (Q3 YTD ¥7.2B + Q4 ¥1.1B = FY ¥8.3B). The low Net Income progress implies an assumed ¥3.0B Net Income in Q4, potentially reflecting tax burdens and one-off factors. No forecast revisions have been made.
Potential drivers of Q4 profit slowdown include seasonality, year-end one-off costs, increases in raw materials and personnel expenses, and emerging geopolitical risks. The full-year Operating Income being forecast to decline indicates that near-term profitability improvements may be limited.
Dividend policy: Annual dividend of ¥8.0 (no interim dividend paid; year-end dividend of ¥8.0 planned). The PDF states a policy that emphasizes a Payout Ratio of 30% as a key indicator. Against Q3 YTD basic EPS of ¥14.51, the annual dividend of ¥8.0 equates to a Payout Ratio of 55.1%, while the full-year forecast EPS of ¥23.91 implies 33.5%, broadly consistent with the 30% policy. The XBRL data note “Interim ¥5.0, year-end ¥11.0” is presumed to be pre-stock split (equivalent to a 3-for-1 split), implying post-split equivalents of interim ¥1.67 and year-end ¥3.67, or ¥5.34 on an annualized basis—this conflicts with the PDF’s ¥8.0 annual figure. The PDF-stated annual ¥8.0 (post-split) should be adopted as the accurate dividend policy.
Share buybacks: No statements regarding buyback execution or plans.
Shareholder benefits: Introduce a shareholder benefit program effective the record date of March 31, 2026. Shareholders holding 1,000 shares or more will be granted a QUO Card NEXT (book card) worth ¥1,000. This is being introduced as part of enhanced shareholder returns.
Total Return Ratio: With no share buybacks, it is synonymous with the Payout Ratio, at 33.5% on a full-year forecast basis. While a 30% Payout Ratio appears maintainable within cash generation capacity, the cash backing for dividends cannot be confirmed due to undisclosed OCF. Total dividend payout is approximately ¥0.27B (¥8.0 × 33.6 million shares), a level sufficiently payable relative to Net Income of ¥4.7B (Q3 YTD).
Short term: Q4 (January–March 2026) earnings trajectory: The full-year forecast assumes a sharp slowdown with Q4 standalone Operating Income of ¥1.1B; year-end demand and cost trends will be in focus. The landing accuracy of Ordinary Income and Net Income will also be key. The introduction of a shareholder benefit program with a record date of March 31, 2026 could increase the shareholder base and have a short-term share price impact.
Long term: Progress against the Medium-Term Management Plan (FY2025–FY2027): Targets include Revenue of ¥250B in FY2030, Ordinary Income Margin of 6%+α, EBITDA of ¥25B (standalone), and ROE of 10%+α. Compared with the FY ending March 2026 targets of Revenue ¥195B and an Ordinary Income Margin of 4.5% (full-year forecast basis), this requires sales CAGR of 5%+ and margin improvement of 1.5pt+. R&D investment and new product launches as a technology-driven company, and expansion of the Environmental Business, are key to long-term growth. Also monitor the sustainability of inbound demand and the impact of geopolitical risks.
Industry positioning (reference information; our research)
Profitability: ROE 2.9% (2.0pt below the industry median of 4.9%), Operating Margin 5.0% (2.3pt below the industry median of 7.3%), Net Margin 3.2% (2.2pt below the industry median of 5.4%). Profitability indicators are generally below the industry median, placing the company at a lower tier within manufacturing.
Soundness: Equity Ratio 55.9% (8.0pt below the industry median of 63.9%), Current Ratio 201.7% (below the industry median of 267%). Financial soundness is slightly below the industry median but remains healthy in absolute terms.
Efficiency: ROA 1.6% (annualized; 1.7pt below the industry median of 3.3%). Asset efficiency is low within the industry, with Total Asset Turnover of 0.505x presumed below the industry average.
Growth: Revenue growth rate +2.4% (0.4pt below the industry median of +2.8%). Growth is standard and roughly in line with the median.
Overall assessment: Profitability and efficiency indicators are below the industry median, placing the company in the lower group within manufacturing. Financial soundness is mid-tier, but improving ROE and ROA remains a challenge. With a 5.0% Operating Margin versus a 7.3% industry median, there is ample room for improvement via SG&A efficiency and gross margin enhancement.
Industry: Manufacturing; Comparison set: FY2025 Q3 results (n=65 companies); Source: Our compilation
Geopolitical risk: Prolonged instability in the Middle East and the Russia–Ukraine situation, and worsening U.S.–China trade policy could raise raw material procurement costs and transportation costs, pressuring gross margins. While the impact is difficult to quantify, under a high cost ratio of 88.1%, a 1% increase in cost is estimated to reduce Operating Income by approximately ¥1.4B (based on ¥144B revenue).
Inflation and personnel cost risk: In an inflationary environment, increases in raw materials and personnel costs risk raising the SG&A ratio and deteriorating gross margins. SG&A is estimated at roughly ¥10B in Q3 YTD (gross profit ¥17B – Operating Income ¥7.2B = ¥9.8B). A 10% rise in personnel costs would depress Operating Income by about ¥1B.
High tax burden risk: The effective tax rate of 44.4% is significantly above the statutory effective tax rate (approximately 30%), restraining Net Income growth. The persistence of the high tax burden (e.g., reversal of deferred tax assets, impact of foreign taxes) is unclear, creating uncertainty about normalization. A 1% reduction in the tax rate would increase Net Income by approximately ¥0.08B.
Investment securities valuation risk: ¥7.7B in net unrealized gains on available-for-sale securities boosted comprehensive income, but a market downturn could result in valuation losses, pressuring comprehensive income and net assets. A 10% write-down on investment securities of ¥45.6B would reduce net assets by approximately ¥4.6B (before tax effect).
Borrowing increase risk: Long-term borrowings surged +79.9% (+¥17B) versus the prior FY-end. In a rising rate environment, higher interest expenses could pressure Ordinary Income. With interest-bearing debt of ¥53.2B, a 1% rise in interest rates would increase annual interest burden by ¥0.5B.
Earnings focal point 1 [Progress of profitability improvement]: The 5.0% Operating Margin is 2.3pt below the industry median of 7.3%, and ROE of 2.9% is well below the industry median of 4.9%. With a medium-term target of an Ordinary Income Margin of 6%+α by FY2030, monitoring progress in gross margin improvement and SG&A efficiency will be key. The Environmental Business’s 14.4% Operating Margin is highly profitable; expansion here is key to lifting overall profitability.
Earnings focal point 2 [Need for cash flow disclosure]: OCF, investing CF, and Free Cash Flow are undisclosed, leaving unclear the cash coverage of dividends, balance with CapEx, and the use of the +¥17B increase in long-term borrowings. While the 30% Payout Ratio policy appears sustainable on a Net Income basis, confirmation of the OCF/Net Income ratio and the ratio of Free Cash Flow to total dividends is necessary. With comprehensive income uplift driven by valuation gains, understanding true cash generation is critical for investment decisions.
Earnings focal point 3 [Drivers of Q4 full-year profit slowdown]: Given the 86.7% progress in Operating Income through Q3 YTD, achieving the full-year forecast presupposes a sharp slowdown to ¥1.1B in Q4 Operating Income. Confirm whether this stems from seasonality, year-end costs, or external environment deterioration, and distinguish between one-off and structural factors. The full-year forecast of Operating Income down -2.1% YoY also suggests a deceleration in the pace of profitability improvement.
This report is an automatically generated earnings analysis prepared by AI through integrated analysis of XBRL earnings release data and the PDF earnings presentation. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by us based on publicly available financial results. Investment decisions are your own responsibility; consult a professional as necessary.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results delivered Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income attributable to owners of parent of ¥4.67B (+4.4% YoY), achieving moderate growth. The company is advancing a three-year Medium-Term Management Plan starting FY ended March 2025 and forecasts full-year Revenue of ¥195B, Ordinary Income of ¥8.7B, and Net Income of ¥7.7B. The dividend policy emphasizes a 30% Payout Ratio, with a planned annual dividend of ¥24 (pre-split basis) for FY ending March 2026. A shareholder benefit program has been newly established to grant QUO Card NEXT to shareholders holding 1,000 shares or more. For FY2030, the company targets Revenue of ¥250B, Ordinary Income of ¥25B, EBITDA of ¥35B, an Ordinary Income Margin of 10% or higher, and ROE of 6% or higher.
For Q3 YTD FY ending March 2026, Revenue was ¥144.32B, up 2.4% YoY, maintaining steady growth. Ordinary Income was ¥7.47B, up 11.5% YoY, achieving double-digit growth and improving profitability. Full-year guidance calls for Revenue of ¥195B, Ordinary Income of ¥8.7B, and Net Income of ¥7.7B, forecasting topline and profit growth. Management targets for FY2030 include Revenue of ¥250B, Ordinary Income of ¥25B, EBITDA of ¥35B, and an Ordinary Income Margin exceeding 10%. A new shareholder benefit program will grant QUO Card NEXT to shareholders holding 1,000 shares or more (first record date: end-March 2026).
While domestic inflation persists, improvements in employment/income conditions and inbound demand underpin a moderate recovery. However, prolonged geopolitical risks (Middle East, Ukraine), U.S. trade policy and worsening relations with China, and rising prices/personnel costs keep the outlook uncertain. The group is advancing initiatives under the three-year Medium-Term Management Plan that began in FY ended March 2025, aiming to achieve its targets.
The company forecasts full-year consolidated results of Revenue ¥195B, Operating Income ¥8.3B, Ordinary Income ¥8.7B, and Net Income attributable to owners of parent ¥7.7B. Dividends: annual ¥24 (pre-split; ¥8 post-split), with a 30% Payout Ratio as a key indicator and performance-linked dividend as a basic policy. ROE is projected at 5.1%, slightly down YoY, while balancing retained earnings with future business development in capital allocation.
Advancing the three-year Medium-Term Management Plan starting FY ended March 2025, focusing on achieving initial-year targets in FY ending March 2026. Strengthening the foundation as a technology-driven company: researchers directly hear customer needs, establishing mass production technologies with unique ideas and state-of-the-art equipment/technologies. Establishing a position as a specialty fine chemical manufacturer: deploying a diverse product portfolio including pharmaceutical intermediates, electronic materials, semiconductor materials, display materials, film materials, photographic materials, imaging materials, and printing materials. Strengthening environmental management: with ISO 14001-certified systems, reducing environmental impact and pursuing sustainability across operations. Enhancing shareholder returns: in addition to a 30% Payout Ratio target, introducing a shareholder benefit program that provides a continued holding incentive for shareholders with 1,000+ shares.
Elevated geopolitical risks: prolonged instability in the Middle East and Russia’s invasion of Ukraine, as well as U.S. trade policy and worsening relations with China. Rising prices and personnel costs: potential pressure on earnings from higher raw materials and labor costs. Market cycle risks: supply-demand fluctuations in the core chemicals markets affecting sales and profits. FX risks: potential impact from exchange rate fluctuations in import/export transactions. Environmental regulatory risks: tighter regulations could affect CapEx and operating costs.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results achieved topline and profit growth with Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income attributable to owners of parent of ¥4.67B (+4.4% YoY). The company is executing a three-year Medium-Term Management Plan starting FY ended March 2025 and expects full-year Revenue of ¥195B and Ordinary Income of ¥8.7B for FY2026. Emphasizing a 30% Payout Ratio, the company plans a full-year dividend of ¥8 (post-split; equivalent to ¥24 pre-split). A shareholder benefit program is newly introduced to grant QUO Card NEXT to shareholders holding 1,000 shares or more. For FY2030, the company aims for Revenue of ¥250B, Ordinary Income of ¥25B, an Ordinary Income Margin of 10%+α, and ROE of 6%+α.
Ordinary Income in the Q3 YTD period was ¥7.47B, up 11.5% YoY, achieving double-digit growth. Full-year FY ending March 2026 guidance remains: Revenue ¥195B, Ordinary Income ¥8.7B, forecasting topline and profit growth. Medium-term management targets set for FY2030 include Revenue of ¥250B, Ordinary Income of ¥25B, and EBITDA of ¥35B. The company will emphasize a 30% Payout Ratio and plans an annual dividend of ¥8 (post-split; ¥24 pre-split). A new shareholder benefit program will grant QUO Card NEXT to shareholders with 1,000+ shares.
For the full year, the company expects Revenue of ¥195B (+4.6% YoY), Operating Income of ¥8.3B (-2.1% YoY), Ordinary Income of ¥8.7B (+6.2% YoY), and Net Income of ¥7.7B (-6.1% YoY). Despite inflationary pressures, improvements in employment/income and inbound demand support a moderate recovery. However, geopolitical risks and rising prices/personnel costs continue to cloud the outlook.
A three-year Medium-Term Management Plan starting FY ended March 2025 has been formulated, and the company is working toward achieving its targets. As a desired position for FY2030, management targets Revenue of ¥250B, Ordinary Income Margin 10%+α, EBITDA ¥35B, and ROE 6%+α. President Shunosuke Sumitomo stated: “We will read the changes of the times, respond to diversifying needs, and take on the challenge of creating new value with a medium- to long-term perspective.”
Executing various measures to achieve the targets of the three-year Medium-Term Management Plan beginning FY ended March 2025. Achieving FY2026 consolidated management targets of Revenue ¥200B, Ordinary Income Margin 6%+α, and EBITDA ¥25B. Introducing a shareholder benefit program to diversify shareholder returns and promote long-term holding, while maintaining a 30% Payout Ratio to strengthen and sustain dividends. Reinforcing the foundation as a technology-driven company by leveraging unique ideas and state-of-the-art equipment/technologies for value creation.
Sustained elevated geopolitical risk from prolonged instability in the Middle East and Russia’s invasion of Ukraine. U.S. trade policy and worsening relations with China. Impacts from rising prices and personnel costs. Potential pressure on consumption from inflation. Ongoing uncertainty in the economic outlook.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results showed Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income attributable to owners of parent of ¥4.67B (+4.4% YoY), delivering topline and profit growth. Domestic economic recovery is supported by improvements in employment/income and inbound demand, though geopolitical and inflationary pressures remain concerns. The company is advancing measures to achieve the three-year Medium-Term Management Plan initiated in FY ended March 2025. Full-year guidance calls for Revenue of ¥195B, Ordinary Income of ¥8.7B, Net Income of ¥7.7B, and a year-end dividend of ¥8 (equivalent to ¥24 pre-split). The company emphasizes a 30% Payout Ratio and has introduced a shareholder benefit program. For FY2030, targets include Revenue of ¥250B, Ordinary Income of ¥25B, Ordinary Income Margin 10%+α, and EBITDA of ¥35B.
Revenue rose 2.4% YoY to ¥144.32B, with the Operating Margin around 5.0%. Ordinary Income increased 11.5% YoY to ¥7.47B, aided by non-operating income. Full-year FY ending March 2026 guidance: Revenue ¥195B, Operating Income ¥8.3B, ROE 5.1%. Annual dividend of ¥24 (pre-split; ¥8 post-split) with a 30% Payout Ratio policy. Shareholder benefit program newly introduced, granting QUO Card NEXT to shareholders holding 1,000+ shares.
The company expects full-year Revenue of ¥195B (+4.6% YoY), with Operating Income at ¥8.3B, broadly flat YoY. Geopolitical risks (Middle East, U.S. trade policy) and rising prices/personnel costs persist, and the company continues to work on strengthening its business base and improving profitability under the three-year plan that started in FY ended March 2025.
President Shunosuke Sumitomo expressed the policy of reading changes of the times, responding to diversifying needs, and taking on the challenge of creating new value with a medium- to long-term perspective. As a technology-driven company, Daito Chemix will leverage unique ideas and state-of-the-art equipment/technologies to establish its position as a specialty fine chemical manufacturer, directly addressing customer needs and emphasizing internal capabilities for mass production.
Steady execution of the three-year Medium-Term Management Plan starting in FY ended March 2025. FY2026 consolidated management targets include Revenue of ¥200B, Ordinary Income Margin of 6% or higher, and EBITDA of ¥13B. For FY2030, the desired position includes Revenue of ¥250B, Ordinary Income Margin of 10%+α, EBITDA of ¥25B and ¥35B. Strengthen customer-direct R&D, utilizing unique perspective/ingenuity and accumulated know-how for product development. Enhance the environmental management system (ISO 14001, Shizuoka sites, Fukui Plant, etc.) and promote SDGs initiatives.
Heightened geopolitical risks such as prolonged instability in the Middle East and Russia’s invasion of Ukraine. Uncertainty stemming from U.S. trade policy and worsening relations with China. Earnings pressure from rising prices and personnel costs. Volatility in raw material and transportation costs raising cost ratios. Guidance and management targets are not guarantees; investors should make decisions at their own risk.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 cumulative results achieved Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income attributable to owners of parent of ¥4.67B (+4.4% YoY). The company is advancing measures to achieve targets under the three-year Medium-Term Management Plan (starting FY ended March 2025). Full-year guidance: Revenue ¥195B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. The dividend policy emphasizes a 30% Payout Ratio, with a per-share dividend of ¥8 (equivalent to ¥24 pre-split) planned for FY ending March 2026. A new shareholder benefit program (1,000 shares or more; QUO Card NEXT) is being introduced from FY ending March 2026.
In FY2025 Q3 YTD, Operating Income was ¥7.18B (+7.3%), with the Operating Margin around 5.0%, improving YoY. Full-year guidance unchanged: Revenue ¥195B, Ordinary Income ¥8.7B, and Operating Income ¥8.3B. The company emphasizes a 30% Payout Ratio and plans an annual dividend of ¥8 (post-split; ¥24 pre-split) for FY ending March 2026. Ambitious FY2030 targets include Revenue of ¥250B, Ordinary Income of ¥25B, and EBITDA of ¥35B. Shareholder benefits newly introduced from end-March 2026 (QUO Card NEXT worth ¥1,000–¥3,000 for 1,000+ shares).
Despite inflationary pressures, improvements in employment/income and inbound demand support a moderate domestic recovery. However, elevated geopolitical risks (Middle East, Ukraine), U.S. trade policy, and worsening relations with China, and rising prices/personnel costs continue to cloud the outlook. Under this environment, the company is advancing measures per the Medium-Term Management Plan to achieve steady growth.
A three-year Medium-Term Management Plan starting FY ended March 2025 has been formulated, and the company is working toward achieving its targets. President and CEO Shunosuke Sumitomo declared a stance of “reading changes of the times, responding to diversifying needs, and taking on the challenge of creating new value with a medium- to long-term perspective.”
Executing various measures to achieve the targets of the three-year plan. FY2026 consolidated management target: Revenue ¥200B, Ordinary Income Margin 6%+α, EBITDA ¥13B. FY2030 desired position: Revenue ¥250B, Ordinary Income Margin 10%+α, EBITDA ¥25B and ¥35B (company standalone). Researchers directly hear customer needs, leveraging unique perspective/ingenuity and accumulated experience/know-how for product development. Strengthen the environmental management system (ISO 14001 certified; Shizuoka sites, Fukui Plant, etc.) and promote SDGs initiatives.
Sustained geopolitical risk from Middle East instability and Russia’s invasion of Ukraine. Uncertainty from U.S. trade policy and worsening relations with China. Pressure from rising prices/personnel costs. Raw material price fluctuations and transportation cost increases. Guidance/targets are not guarantees; investors should decide at their own risk.
AI analysis of the PDF earnings presentation
Daito Chemix achieved Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income of ¥4.67B (+4.4% YoY) in Q3 FY ending March 2026, delivering topline and profit growth. The three-year Medium-Term Management Plan began in FY ended March 2025. Full-year guidance is Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. Dividend policy is a 30% Payout Ratio with a per-share dividend of ¥8 post-split (¥24 pre-split). A shareholder benefit program is newly introduced, granting QUO Card NEXT to shareholders with 1,000+ shares. As a technology-driven company, the firm deploys pharmaceutical intermediates, imaging materials, electronic materials, semiconductor materials, and display materials, promoting environmental management (ISO 14001 certified) and SDGs initiatives.
Q3 YTD delivered Revenue +2.4% and Ordinary Income +11.5%, maintaining growth. Initiatives are being advanced under the three-year plan starting FY ended March 2025. From FY ending March 2026, a shareholder benefit program is newly introduced, granting QUO Card to shareholders with 1,000+ shares. For FY2026 full-year, ROE is projected at 5.1%, and the dividend policy (annual ¥8) emphasizes a 30% Payout Ratio. As a technology-driven company, it leverages R&D and environmental management to position as a specialty fine chemical manufacturer.
In an environment of geopolitical risk and inflationary pressures, the company continues to advance initiatives under the three-year plan. Full-year guidance envisages Revenue of ¥195.0B and Ordinary Income of ¥8.7B, with ROE at 5.1%.
The company aims to maintain a 30% Payout Ratio and pay dividends in line with performance, while considering retained earnings to prepare for future business developments. It emphasizes sound management and corporate value enhancement to bolster shareholder returns. President Shunosuke Sumitomo expressed a stance of “reading changes of the times, responding to diversifying needs, and creating new value with a medium- to long-term perspective.”
Advancing the three-year Medium-Term Management Plan (starting FY ended March 2025). FY2026 targets: Revenue ¥200B, Ordinary Income ¥13B, FY2030 targets: Revenue ¥250B, Ordinary Income ¥25B. Strengthening foundations as a technology-driven company: researchers directly hear customer needs, leveraging unique perspective/ingenuity and accumulated know-how; improving mass-production technology and utilizing state-of-the-art equipment for high-quality stable supply. Strengthening environmental management: ISO 14001-certified plants (Shizuoka site, Shizuoka Plant, Fukui Plant) reduce environmental impact and promote SDGs. Enhancing shareholder returns: maintain a 30% Payout Ratio and introduce a shareholder benefit program for shareholders with 1,000+ shares.
Elevated geopolitical risks (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Impacts from rising prices and personnel costs. Raw materials/transportation cost volatility (manufacturing-specific). Guidance/targets/FY2030 desired position are not guarantees; investment decisions are at the investor’s own risk.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results achieved Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income of ¥4.67B (+4.4% YoY). Full-year guidance is Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. The three-year Medium-Term Management Plan starting FY ended March 2025 is underway, with FY2026 consolidated management targets of Ordinary Income Margin 6%+α and EBITDA of ¥25B, and a long-term vision for FY2030 targeting Revenue of ¥250B, Ordinary Income of ¥25B, Ordinary Income Margin of 10%+α, and EBITDA of ¥35B. Dividend policy targets a 30% Payout Ratio, with a full-year dividend of ¥24 (post-split ¥8), and a new shareholder benefit program is introduced.
Q3 YTD delivered Revenue of ¥144.32B (+2.4%) and Ordinary Income of ¥7.47B (+11.5%), maintaining growth. Full-year guidance is Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B, expecting topline and profit growth. Medium-term targets set for FY2026 include Ordinary Income Margin of 6%+α, and for FY2030: Ordinary Income of ¥25B and Ordinary Income Margin of 10%+α. Dividend policy focuses on a 30% Payout Ratio, with an annual dividend of ¥24 (equivalent to ¥8 post-split). A shareholder benefit program (QUO Card NEXT) is newly introduced for shareholders with 1,000+ shares from FY ending March 2026.
A moderate recovery continues, supported by improvements in employment/income and inbound demand, while geopolitical risks and inflationary pressures persist. The company is progressing initiatives aligned with the three-year plan that began in FY ended March 2025.
President and CEO Shunosuke Sumitomo emphasized understanding changes of the times and responding to diverse needs, with a medium- to long-term focus on creating new value. Researchers directly hear customer needs, leveraging unique perspective, accumulated know-how, and mass production technology. Emphasizing quality, safety, and environmental management, the company aims to support its position as a technology-driven “specialty fine chemical manufacturer.”
Formulated a three-year Medium-Term Management Plan starting in FY ended March 2025, executing various measures to achieve targets. FY2026 management targets: Revenue ¥200B, Ordinary Income Margin 6%+α, and EBITDA ¥25B. FY2030 desired position: Revenue ¥250B, Ordinary Income ¥25B, Ordinary Income Margin 10%+α, and EBITDA ¥35B. Strengthen environmental management (ISO 14001 certified, Shizuoka site, Technology Development Center, etc.) and contribute to SDGs. Enhance shareholder returns with a 30% Payout Ratio and a shareholder benefit program for shareholders with 1,000+ shares.
Sustained geopolitical risk (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Ongoing inflation and rising personnel costs. Variability in inbound demand (uncertain sustainability of demand increase from improved employment/income). Guidance, targets, and FY2030 desired position are not guarantees; investors are responsible for their own decisions.
AI analysis of the PDF earnings presentation
Daito Chemix’s Q3 FY ending March 2026 results achieved Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income of ¥4.67B (+4.4% YoY). The three-year Medium-Term Management Plan started in FY ended March 2025. Full-year guidance is Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. Dividend policy emphasizes a 30% Payout Ratio with a full-year dividend of ¥8 (¥24 pre-split), and a shareholder benefit program is newly introduced (QUO Card NEXT for 1,000+ shares).
For April–December 2025, Revenue was ¥144.32B (+2.4% YoY) and Ordinary Income was ¥7.47B (+11.5% YoY), delivering topline and profit growth. Full-year guidance for FY ending March 2026 is Revenue ¥195.0B and Ordinary Income ¥8.7B, forecasting YoY growth. Dividend policy emphasizes a 30% Payout Ratio, with an annual dividend of ¥8 (post-split; ¥24 pre-split), representing a 50% increase YoY. A shareholder benefit program will be newly introduced from end-March 2026, granting QUO Card NEXT to shareholders with 1,000+ shares. Medium-term management targets include FY2026 Revenue of ¥200B and Ordinary Income of ¥13B (EBITDA margin 6%+α).
Despite inflation, improvements in employment/income and inbound demand support a moderate recovery. However, elevated geopolitical risks (Middle East, Ukraine), U.S. trade policy, and worsening relations with China, and rising prices/personnel costs keep the outlook uncertain. The company is advancing initiatives per the three-year plan starting FY ended March 2025.
President Shunosuke Sumitomo expressed a policy of reading changes of the times, responding to diversifying needs, and taking on the challenge of creating new value with a medium- to long-term perspective. The company emphasizes its foundation as a technology-driven firm, where researchers directly hear customer needs, leveraging unique ideas, experience, know-how, and mass-production capabilities.
Formulated a three-year Medium-Term Management Plan starting FY ended March 2025, executing initiatives. FY2026 management targets: Revenue ¥200B, Ordinary Income ¥13B, and EBITDA margin 6%+α. FY2030 desired position: Revenue ¥250B, Ordinary Income ¥25B, Ordinary Income Margin 10%+α, EBITDA ¥35B, and EBITDA margin exceeding ¥25B. Strengthening shareholder returns with a 30% Payout Ratio and a new shareholder benefit program (QUO Card NEXT for 1,000+ shares; initial record date end-March 2026, and thereafter dependent on holding period).
Elevated geopolitical risks (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Impacts from inflation and personnel cost increases. Continued uncertainty in the economic outlook.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results achieved Revenue of ¥144.32B (+2.4% YoY), Ordinary Income of ¥7.47B (+11.5% YoY), and Net Income attributable to owners of parent of ¥4.67B (+4.4% YoY). The company is executing a three-year Medium-Term Management Plan and expects full-year Revenue of ¥195.0B, Ordinary Income of ¥8.7B, and Net Income of ¥7.7B. It plans an annual dividend of ¥8 (post-split; ¥24 pre-split) with a 30% Payout Ratio, and will newly introduce a shareholder benefit program for shareholders with 1,000+ shares from FY ending March 2026.
Revenue increased 2.4% YoY to ¥144.32B and Ordinary Income rose 11.5% YoY to ¥7.47B. Full-year guidance is maintained at Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B, with a projected ROE of 5.1%. A 30% Payout Ratio is emphasized, with an annual dividend of ¥8 (post-split) planned; the shareholder benefit program will commence from end-March 2026.
Full-year expectations are Revenue ¥195.0B (+4.6% YoY), Operating Income ¥8.3B (-2.1% YoY), Ordinary Income ¥8.7B (+6.2% YoY), and Net Income ¥7.7B (-6.1% YoY), with ROE at 5.1%. Despite geopolitical risks (Middle East, U.S. trade policy) and rising prices/personnel costs, the company anticipates a moderate recovery.
President and CEO Shunosuke Sumitomo stated a policy of reading changes of the times, responding to diversifying needs, and taking on the challenge of creating new value. Leveraging a technology-driven foundation, researchers directly hear customer needs, using unique perspectives and accumulated experience/know-how to enable mass production, while emphasizing internal reserves with a performance-linked dividend policy.
Executing a three-year Medium-Term Management Plan and measures toward targets. Management objectives for FY2026: Revenue ¥200B, Ordinary Income Margin 6%+α, and EBITDA ¥25B. Desired FY2030 position: Revenue ¥250B, Ordinary Income Margin 10%+α, EBITDA ¥35B. Enhancing shareholder returns through a 30% Payout Ratio target and a new shareholder benefit program, and strengthening technology-driven capabilities.
Elevated geopolitical risks (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Impacts from rising prices and personnel costs. Lack of guarantee regarding guidance/targets/FY2030 desired position; investment decisions are at the investor’s own risk.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results were Revenue ¥144.32B (+2.4% YoY), Ordinary Income ¥7.47B (+11.5% YoY), and Net Income ¥4.67B (+4.4% YoY), achieving topline and profit growth. The full-year forecast remains Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. The three-year Medium-Term Management Plan started in FY ended March 2025, with FY2026 consolidated management targets of Revenue ¥200B, Ordinary Income ¥13B, EBITDA ¥25B, Ordinary Income Margin 6%+α, and ROE 5.1%, and a FY2030 vision of Revenue ¥250B, Ordinary Income ¥25B, EBITDA ¥35B, and Ordinary Income Margin 10%+α. A new shareholder benefit program (QUO Card NEXT for 1,000+ shares) is introduced to enhance shareholder returns.
The three-year Medium-Term Management Plan commenced in FY ended March 2025, with FY2026 targets of Revenue ¥200B, Ordinary Income ¥13B, Ordinary Income Margin 6%+α, and ROE 5.1%. For FY2030, the company aims for Revenue ¥250B, Ordinary Income ¥25B, EBITDA ¥35B, and Ordinary Income Margin 10%+α. Dividend policy maintains a 30% Payout Ratio with an annual dividend of ¥8 (post-split; ¥24 pre-split). The shareholder benefit program will grant QUO Card NEXT to shareholders with 1,000+ shares from FY ending March 2026.
A moderate recovery is expected against a backdrop of improvements in employment/income and inbound demand, while geopolitical risks and inflationary pressures persist. The company is progressing initiatives under the three-year plan and expects full-year topline and profit growth.
President Shunosuke Sumitomo stated a policy of reading changes of the times, responding to diversifying needs, and taking on the challenge of creating new value with a medium- to long-term perspective. Researchers directly hear customer needs, leveraging unique ideas and mass-production technologies, while maintaining a comprehensive system for quality assurance, safety, and environmental management.
Advancing the three-year plan starting FY ended March 2025 and executing measures to achieve targets. FY2026 management targets: Revenue ¥200B, Ordinary Income ¥13B, Ordinary Income Margin 6%+α, EBITDA ¥25B. FY2030 vision: Revenue ¥250B, Ordinary Income ¥25B, Ordinary Income Margin 10%+α, EBITDA ¥35B. Diversifying shareholder returns with a new benefit program and maintaining a 30% Payout Ratio. Strengthening foundations as a technology-driven specialty fine chemical manufacturer.
Elevated geopolitical risks (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Impacts from inflation and rising personnel costs. The guidance/targets/FY2030 vision are not guarantees; investment decisions are the investor’s responsibility.
AI analysis of the PDF earnings presentation
Daito Chemix Corporation’s Q3 FY ending March 2026 results show steady performance: Revenue ¥144.32B (+2.4% YoY), Ordinary Income ¥7.47B (+11.5% YoY), and Net Income ¥4.67B (+4.4% YoY). Full-year guidance is Revenue ¥195.0B, Ordinary Income ¥8.7B, and Net Income ¥7.7B. The three-year Medium-Term Management Plan starting FY ended March 2025 is in progress, with an emphasis in FY2026 on Ordinary Income Margin 6%+α and EBITDA margin of ¥25B. For FY2030, targets include Revenue of ¥250B, Ordinary Income of ¥25B, Ordinary Income Margin 10%+α, and EBITDA of ¥35B. Dividend policy plans an annual ¥24 (30% Payout Ratio target), with a new shareholder benefit program introduced. The company positions itself as a technology-driven specialty fine chemical manufacturer.
Q3 YTD Ordinary Income increased 11.5% YoY to ¥7.47B, achieving double-digit growth. Full-year guidance is Revenue ¥195.0B (+4.6% YoY), with four consecutive years of revenue growth expected. A shareholder benefit program will be newly introduced from FY ending March 2026, granting QUO Card NEXT to shareholders with 1,000+ shares. The dividend policy focuses on a 30% Payout Ratio with an annual ¥24 (post-split equivalent) planned. Medium-term targets for FY2030 are Revenue ¥250B, Ordinary Income Margin >10%, and EBITDA ¥35B.
Despite inflation and elevated geopolitical risks, improvements in employment/income and inbound demand support a moderate domestic recovery. The company is executing initiatives aligned with the three-year Medium-Term Management Plan that began in FY ended March 2025.
President Shunosuke Sumitomo stated: “We will read changes of the times, respond to diversifying needs, and take on the challenge of creating new value with a medium- to long-term perspective.” Since assuming office on June 24, 2022, he has aimed for consecutive revenue increases, with focus on profitability and shareholder returns, while leveraging unique R&D and equipment to strengthen the technology-driven foundation.
Steady execution of the three-year plan starting FY ended March 2025. Establish a long-term vision for FY2030 (Revenue ¥250B, Ordinary Income Margin >10%, EBITDA ¥35B). Researchers directly hear customer needs, using unique perspectives and accumulated know-how for product development. Build environmental management systems (ISO 14001 certification, Shizuoka sites, Technology Development Center, etc.) and contribute to SDGs. Strengthen shareholder returns with a 30% Payout Ratio and new benefit program for shareholders with 1,000+ shares.
Sustained geopolitical risks (Middle East, Russia–Ukraine). U.S. trade policy and worsening relations with China. Impacts from inflation and rising personnel costs. Raw material price and transportation cost volatility. Demand fluctuation risks amid an uncertain recovery.
---End of Report---